Tarsus Pharmaceuticals, Inc.
TARS · XNASCIK 1819790fmd_0795GCWMV71Q5CE0F70A7F9FW7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
Latest annual · FY2025
Millions- Total revenues
- 451
- Operating income
- (71)
- Net income
- (66)
- Free cash flow
- (22)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 195
- Gross profit
- 181
- Operating income
- (662)
- Net income
- (668)
- Free cash flow
- (7)
Daily close · TARSIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions76.80 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +159.5%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Tarsus Pharmaceuticals, Inc. (TARS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $451.4 million | $183 million | +146.7% | 10-K 2026-02-23 · proof |
| Operating income | -$71 million | -$120.6 million | 10-K 2026-02-23 · proof | |
| Net income | -$66.4 million | -$115.6 million | 10-K 2026-02-23 · proof | |
| Cash from operating activities | -$12.5 million | -$83 million | 10-K 2026-02-23 · proof | |
| Free cash flow | -$22.3 million | -$84.6 million | 10-K 2026-02-23 · proof | |
| Total assets | $562.2 million | $377 million | +49.1% | 10-K 2026-02-23 · proof |
| Total liabilities | $218.7 million | $152.5 million | +43.5% | 10-K 2026-02-23 · proof |
| Cash and cash equivalents | $183.6 million | $94.8 million | +93.7% | 10-K 2026-02-23 · proof |
- What was Tarsus Pharmaceuticals, Inc. (TARS)'s revenue in fiscal 2025?
- Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $183 million the year before (+146.7%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was Tarsus Pharmaceuticals, Inc. (TARS)'s operating income in fiscal 2025?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating income of -$71 million for fiscal 2025 (the year ended Dec 31, 2025), against -$120.6 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was Tarsus Pharmaceuticals, Inc. (TARS)'s net income in fiscal 2025?
- Tarsus Pharmaceuticals, Inc. (TARS) reported net income of -$66.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$115.6 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was Tarsus Pharmaceuticals, Inc. (TARS)'s cash from operating activities in fiscal 2025?
- Tarsus Pharmaceuticals, Inc. (TARS) reported cash from operating activities of -$12.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$83 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What was Tarsus Pharmaceuticals, Inc. (TARS)'s free cash flow in fiscal 2025?
- Tarsus Pharmaceuticals, Inc. (TARS) reported free cash flow of -$22.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$84.6 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are Tarsus Pharmaceuticals, Inc. (TARS)'s total assets?
- As of Dec 31, 2025, Tarsus Pharmaceuticals, Inc. (TARS) reported total assets of $562.2 million, against $377 million a year earlier (+49.1%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are Tarsus Pharmaceuticals, Inc. (TARS)'s total liabilities?
- As of Dec 31, 2025, Tarsus Pharmaceuticals, Inc. (TARS) reported total liabilities of $218.7 million, against $152.5 million a year earlier (+43.5%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
- What are Tarsus Pharmaceuticals, Inc. (TARS)'s cash and cash equivalents?
- As of Dec 31, 2025, Tarsus Pharmaceuticals, Inc. (TARS) reported cash and cash equivalents of $183.6 million, against $94.8 million a year earlier (+93.7%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TARS&period_type=annual&limit=5"Information only, not investment advice.